Quick 5 min look at their results:
- Targeted adults (Neuren was 5-15 years old)
- Smaller sample size (25 patients vs Neuren's 82)
- Much smaller dose (5mg daily vs up to 200mg/kg for Neuren's trial)
- More statistically significant results in CGI(P values of 0.014 vs Neuren's 0.029)
- Similar statistically significant results in RSBQ (0.048 vs Neuren's 0.042)
Looks good for Anavex.
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-4
-
- There are more pages in this discussion • 163 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |